| 产品名称： | PA-1 PA1 |
|---|---|
| 商品货号： | TS211149 |
| Organism： | Homo sapiens, human |
| Tissue： | ovary; derived from metastatic site: ascites |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | teratocarcinoma |
| Age： | 12 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Derivation： | The line was established from cells taken from ascitic fluid.
|
| Clinical Data： | 12 years Caucasian female |
| Antigen Expression： | HLA A28, B12 |
| Oncogene： | N-ras + (activated) |
| Tumorigenic： | Yes |
| Effects： | Yes, Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells. |
| Comments： | The cells form tightly knit colonies, and differentiate to form embryoid bodies when cultured in low serum concentration, or at low plating densities or when treated with 5-bromo-2-deoxyuridine.
The embryonic antigen PCC4 is expressed, but F9 is not detectable.
|
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Eagles Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: heat-inactivated fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 mL of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37°C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:10 is recommended
Medium Renewal: 2 to 3 times per week |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 9,12 D13S317: 9,10 D16S539: 9,12 D5S818: 11 D7S820: 9 THO1: 7,9 TPOX: 11 vWA: 15,17 |
| Isoenzymes： | G6PD, B |
| Name of Depositor： | BC Giovanella |
| Deposited As： | Homo sapiens |
| References： | . . In Vitro 10: 382, 1974. Zeuthen J, et al. Characterization of a human ovarian teratocarcinoma-derived cell line. Int. J. Cancer 25: 19-32, 1980. PubMed: 6931103 Giovanella BC, et al. Heterotransplantation of human malignant tumors in "nude" thymusless mice. II. Malignant tumors induced by injection of cell cultures derived from human solid tumors. J. Natl. Cancer Inst. 52: 921-930, 1974. PubMed: 4524119 Tainsky MA, et al. An activated rasN gene: detected in late but not early passage human PA1 teratocarcinoma cells. Science 225: 643-645, 1984. PubMed: 6740333 McGowan-Jordan IJ, et al. Suppression of tumorigenicity in human teratocarcinoma cell line PA-1 by introduction of chromosome 4. Cancer Res. 54: 2568-2572, 1994. PubMed: 8168081 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | PA-1 PA1 |
|---|---|
| 商品货号： | TS211149 |
| Organism： | Homo sapiens, human |
| Tissue： | ovary; derived from metastatic site: ascites |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | teratocarcinoma |
| Age： | 12 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Derivation： | The line was established from cells taken from ascitic fluid.
|
| Clinical Data： | 12 years Caucasian female |
| Antigen Expression： | HLA A28, B12 |
| Oncogene： | N-ras + (activated) |
| Tumorigenic： | Yes |
| Effects： | Yes, Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells. |
| Comments： | The cells form tightly knit colonies, and differentiate to form embryoid bodies when cultured in low serum concentration, or at low plating densities or when treated with 5-bromo-2-deoxyuridine.
The embryonic antigen PCC4 is expressed, but F9 is not detectable.
|
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Eagles Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: heat-inactivated fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 mL of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37°C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:10 is recommended
Medium Renewal: 2 to 3 times per week |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 9,12 D13S317: 9,10 D16S539: 9,12 D5S818: 11 D7S820: 9 THO1: 7,9 TPOX: 11 vWA: 15,17 |
| Isoenzymes： | G6PD, B |
| Name of Depositor： | BC Giovanella |
| Deposited As： | Homo sapiens |
| References： | . . In Vitro 10: 382, 1974. Zeuthen J, et al. Characterization of a human ovarian teratocarcinoma-derived cell line. Int. J. Cancer 25: 19-32, 1980. PubMed: 6931103 Giovanella BC, et al. Heterotransplantation of human malignant tumors in "nude" thymusless mice. II. Malignant tumors induced by injection of cell cultures derived from human solid tumors. J. Natl. Cancer Inst. 52: 921-930, 1974. PubMed: 4524119 Tainsky MA, et al. An activated rasN gene: detected in late but not early passage human PA1 teratocarcinoma cells. Science 225: 643-645, 1984. PubMed: 6740333 McGowan-Jordan IJ, et al. Suppression of tumorigenicity in human teratocarcinoma cell line PA-1 by introduction of chromosome 4. Cancer Res. 54: 2568-2572, 1994. PubMed: 8168081 |
